| 000 | 01753 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516141056.0 | ||
| 264 | 0 | _c20140117 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1399-3046 | ||
| 024 | 7 |
_a10.1111/petr.12061 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMårtensson, T | |
| 245 | 0 | 0 |
_aIncreased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. _h[electronic resource] |
| 260 |
_bPediatric transplantation _cMay 2013 |
||
| 300 |
_a285-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Tract _xdrug effects |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdiagnosis |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aLeukemia, Myelomonocytic, Acute _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xtherapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPriftakis, P | |
| 700 | 1 | _aCasswall, T | |
| 700 | 1 | _aRingdén, O | |
| 700 | 1 | _aMattsson, J | |
| 700 | 1 | _aRemberger, M | |
| 700 | 1 | _aHassan, M | |
| 700 | 1 | _aGustafsson, B | |
| 773 | 0 |
_tPediatric transplantation _gvol. 17 _gno. 3 _gp. 285-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/petr.12061 _zAvailable from publisher's website |
| 999 |
_c22580700 _d22580700 |
||